PlainPharmaWatch

CMS Open Payments · Tool

Cipla USA Inc. vs TerSera Therapeutics LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

TerSera Therapeutics LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,704, versus 1,419 for the other company. Its single largest recorded recipient represents 40.7% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Cipla USA Inc.
HHI 1,419 · top recipient 28.8%
Ranked #893 of 1,838 companies by HHI
TerSera Therapeutics LLC
HHI 1,704 · top recipient 40.7%
Ranked #814 of 1,838 companies by HHI

Payment Overview

Company A

Cipla USA Inc.

Total Payments
$2.6M
% of Industry
0.0%
Transactions
2,355
Avg per Transaction
$1.1K
Recipients
80
Avg per Recipient
$32.2K
Payment Types
2
Top Payment Type
Compensation for Services Other Than Consulting
Total Payments
$2.5M
% of Industry
0.0%
Transactions
5,997
Avg per Transaction
$421.12
Recipients
5,974
Avg per Recipient
$422.74
Payment Types
5
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Cipla USA Inc. vs TerSera Therapeutics LLC - total reported payments in CMS Open Payments PY2024

Cipla USA Inc.$2.6MTerSera Therapeutics LLC$2.5M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Cipla USA Inc.

Compensation for Services Other Than Consulting $2.2M

99.8%

Consulting Fee $3.5K

0.2%

TerSera Therapeutics LLC

Consulting Fee $350.2K

58.1%

Food and Beverage $147.0K

24.4%

Travel and Lodging $63.3K

10.5%

Space Rental or Facility Fees $37.0K

6.1%

Education $5.5K

0.9%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Cipla USA Inc.

  1. 1

    MICHAEL SHANE HULL

    $637,274.79 · 14 txns

  2. 2

    KAREN DIANE DUNN

    $258,040.17 · 12 txns

  3. 3

    JEFFREY PAUL TILLINGHAST

    $253,994.76 · 7 txns

  4. 4

    JOHN F ZWETCHKENBAUM

    $192,920.00 · 8 txns

  5. 5

    STEVEN FRANK WEINSTEIN

    $191,674.37 · 6 txns

TerSera Therapeutics LLC

  1. 1

    GLADSTONE MCDOWELL

    $245,473.73 · 334 txns

  2. 2

    ANDREA STEBEL

    $27,305.94 · 70 txns

  3. 3

    ERIC LIU

    $16,283.82 · 60 txns

  4. 4

    Univer.Of Cincinnati Med Center Llc

    $10,000.00 · 2 txns

  5. 5

    BRIAN BRUEL

    $7,662.03 · 23 txns

Summary Comparison

Metric Cipla USA Inc. TerSera Therapeutics LLC
Total Payments $2.6M $2.5M
% of Industry Total 0.0% 0.0%
Transaction Count 2,355 5,997
Avg per Transaction $1.1K $421.12
Recipient Count 80 5,974
Avg per Recipient $32.2K $422.74
Payment Type Count 2 5
Top Payment Type Compensation for Services Other Than Consulting Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.